Products for Research Use Only
RegisterLogin

Cevidoplenib

CAT: 0804-HY-109082-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-109082-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cevidoplenib (SKI-O-703) is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases with IC50s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively[1][2][3].
CAS Number
1703788-21-9
Product Name Alternative
SKI-O-703
UNSPSC
12352005
Target
Syk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cevidoplenib.html
Purity
99.58
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(C1CC1)C2=CN(C)C3=C2C=C(NC4=NC=CC(N5N=C(C)C(CN6OC[C@@H](O)C6)=C5)=N4)C=C3
Molecular Formula
C25H27N7O3
Molecular Weight
473.53
References & Citations
[1]International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information, Vol. 31, No. 4, 2017.|[2]cevidoplenib dimesylate.|[3]Cho S, et al. A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Clin Exp Immunol. 2023 Mar 8;211 (1) :31-45.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Alternative Products

CatalogName
BA9025-10Cevidoplenib
GTR19170615-01Cevidoplenib dimesylate
M28906-01Cevidoplenib dimesylate hydrochloride

Popular Products